The company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
WuXi STA’s drug product site in Wuxi City offers a full range of services including formulation development and manufacturing for a broad range of oral and injectable dosage forms
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
This ninth update of WHO’s guideline on therapeutics includes a recommendation that casirivimab-imdevimab not be used for patients infected with the Omicron variant
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier
The phosphine ligand is available on the kilo scale for the first time, providing scientists with a powerful solution for cross-coupling chemistry
At the new centre, customers get a real-time experience of the process of genetic testing and actionable plans in preventive healthcare under the expertise of certified genetic counsellors
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
High level of vaccine efficacy maintained over a 6-month period of surveillance
This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Innovative TIMScore for dda-PASEF and dia-PASEF libraries, combined with TIMS DIA-NN identifies 9000 protein groups from 200 ng K562 lysate in just 35 min gradient
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
Clinical trial supply company strengthens its presence in the European Union
Subscribe To Our Newsletter & Stay Updated
